DestiNA Genomics

DestiNA Genomics has developed a proprietary, platform-agnostic chemistry (DGL-Tech/ChemiRNA Tech) that transforms standard immunoassay workflows into tools for direct, extraction-free miRNA and protein detection. This approach aims to unlock the use of miRNA biomarkers in drug development and diagnostics by providing more stable, accurate, and comprehensive data, including full isomiR profiles. The company is currently commercializing Research Use Only (RUO) kits for hepatotoxicity testing and is seeking licensing partners to expand the application of its core technology.

Patented DGL-Tech/ChemiRNA Tech: A PCR-free, chemical detection platform using SMART-Bases and PNA probes for direct, extraction-free, single-well multi-omic (miRNA + protein) detection on standard immunoassay readers.

DestiNA competes with large molecular diagnostics companies (e.g., Qiagen, Roche, Thermo Fisher) that dominate the PCR-based miRNA assay market, as well as newer sequencing-based (NGS) liquid biopsy firms. Its key differentiation is the combination of PCR-free operation, full isomiR detection, and single-well multi-omic capability, which is not offered by standard approaches.